IFPMA at the World Health Summit

9 - 11 October 2016 World Health Summit, WHS Foundation GmbH, c/o Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

9 - 11 October 2016


16:00 to 18:30


World Health Summit, WHS Foundation GmbH, c/o Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany


This event has now passed. To browse our upcoming events click here.

IFPMA will be present at the World Health Summit (WHS) with representatives in a special session entitled ‘Innovation in health: The contribution of biologic medicines to public health’ that will take place on Monday 10 October 2016, from 16:00 to 18:30 in Berlin.
The objective of the biologics session is to highlight the role of biologic medicine in responding to public health needs, including the benefit to patients, healthcare providers and caregivers and discuss multi-sectorial commitment to advancing biologics policy action, as well as suitable and equitable access to innovation in health that balances stakeholder needs.


Monday, 10 October 16:00 - 16:10

Biologics Session overview
Introduction to the Session:
‘Innovation in health: The contribution of biologic medicines to public health’


Keynote: Current and Future Role of Biologics


Panel: Innovation in Health
-Focus on value to public health
-Focus on the patient perspective
-Focus on the biologics story
-Focus on health economics


Implications of Inaction in innovation
-Facilitated discussion with all speakers


Taking Action Together
-The role and responsibility of various stakeholders




Brendan Shaw Assistant Director General, IFPMA

Brendan Shaw is Assistant Director General at IFPMA and was appointed in 2014. Brendan assists the Director General in leading on a range of policy and representational functions particularly in innovation policy, intellectual property, trade, health technology assessment, ethics, compliance and vaccines.
Brendan holds an honors degree in economics from the University of Queensland and a PhD in management, business and economics from Monash University.
Prior to joining IFPMA, Brendan was Chief Executive of the Australian pharmaceutical industry association, Medicines Australia, and before that was the senior executive at MA in charge of health policy and research. Brendan has also worked as an economist and policy advisor in government and politics, in academia and as a consultant.

Janis Bernat Associate Director, Biotherapeutics & Scientific Affairs, IFPMA

Janis Bernat joined IFPMA in 2006 to work with the Vaccines Committee and Influenza Vaccine Supply Task Force. She is currently responsible for the policy and technical work in the area of biotherapeutic and biosimilar medicines and leads the organization’s regulatory team.
Janis holds degrees in agriculture, food science, and mass communications from several US universities.
Prior to joining IFPMA, she worked for a US-based multi-national food company in quality assurance and regulatory compliance.

Durhane Wong Rieger President, Canadian Organization for Rare Disorders

Durhane Wong-Rieger, Ph.D serves as Member of Advisory Board of Phsn-tv. Ms. Wong-Rieger also serves as President and Chief Executive Officer of Anemia Institute for Research and Education. Beyond her leadership role with the Anemia Institute, Ms. Wong-Rieger is also founder and head of Consumer Advocare Network, a national network to provide a common voice for consumer-based healthcare organizations. As president of the Canadian Hemophilia Society, she advocated on behalf of consumers infected through Canada’s tainted blood system. From 1984 to 1999, she was professor of psychology at the University of Windsor in Ontario, Canada. She has a BA in psychology from Barnard College in New York and an MA and PhD in social psychology from McGill University in Montreal. She is author of two books and numerous articles. She is a frequent lecturer and conducts workshops and training for business organizations and community groups.

Paul J. Declerck Dean, Faculty of Pharmaceutical SciencesUniversity of Leuven

Professor Paul Declerck obtained a PhD in Pharmaceutical Sciences from the University of Leuven (Belgium) in 1984. After a post doctoral training in the Laboratory of Biochemical Cytology with Prof. Dr. de Duve at the Rockefeller University in New York (USA) he joined in 1986 the Center for Molecular and Vascular Biology at the University of Leuven. In 1991, he was appointed professor of Pharmaceutical Biotechnology at this university. He became full professor in 1997. His research is focused on structure-function relationships of (recombinant) proteins and on the development of monoclonal antibodies for research, diagnostic and therapeutic purposes. Professor Declerck has given numerous invited lectures at international meetings and has authored more than 190 scientific papers in peer-reviewed journals. He is a member of various international scientific advisory boards and vice-president of the commission of medicines for human use of the Federal Agency for Medicinal and Health Products (Belgium).

Axel Mühlbacher Deputy Dean, Department of Health, Nursing, Hochschule Neubrandenburg

Member Managing Board, Accreditation Agency for Study Programs in Special ducation, Care, Health Sciences and Social Work (AHPGS), Freiburg, Germany
Deputy Dean, Department of Health, Nursing
and Management, Hochschule brandenburg, Germany

Med George Marckmann President of the Institute for Ethic, History and Theory in Practice, University of Munich

W3-Professorship for Ethics, History and Theory of Medicine and Board of the eponymous Institute at the Ludwig-Maximilians University of Munich


Supporting documents